Pancreatic Cancer Research

ResearcherNational Health Research InstitutesNo recent work listed

Gyorgy Bodoky

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5659-2020; OpenAlex author ID A5033985179. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
32
Papers, trials and grants by year

2012: 2 papers · 2013: none · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: 2 papers · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: none · 2023: 1 paper

Papers 9

  1. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. Co-author DOI 10.1200/jco.22.01134↗
  2. Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPO… Co-author DOI 10.1097/mpa.0000000000001455↗
  3. Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre pha… Co-author DOI 10.1177/1758835918818351↗
  4. Efficacy and Safety of FOLFIRINOX in Locally Advanced Pancreatic Cancer. A Single Center Experience. Last author DOI 10.1007/s12253-016-0176-0↗
  5. Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer. Co-author DOI 10.1093/annonc/mdw607↗
  6. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, rand… Co-author DOI 10.1016/s0140-6736(15)00986-1↗
  7. Clinical benefit response in pancreatic cancer trials revisited. Co-author DOI 10.1159/000357965↗
  8. A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced o… Co-author DOI 10.1007/s10637-011-9687-4↗
  9. Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial. Co-author DOI 10.1093/annonc/mdr379↗

Closest collaborators

The 25 strongest of 32 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Werner Scheithauer · 2 shared papers, 2014–2019 · strength 0.14
  2. Richard Herrmann · 2 shared papers, 2014–2019 · strength 0.14
  3. Bengt L. G. Glimelius · 2 shared papers, 2014–2019 · strength 0.14
  4. Jean‐Frédéric Blanc · 1 shared paper, 2020 · strength 0.11
  5. Andrew Peter Dean · 1 shared paper, 2020 · strength 0.11
  6. Kyung-Hun Lee · 1 shared paper, 2020 · strength 0.11
  7. Bruce Belanger · 1 shared paper, 2020 · strength 0.11
  8. Li‐Tzong Chen · 1 shared paper, 2020 · strength 0.11
  9. Jens Thomas Siveke · 1 shared paper, 2020 · strength 0.11
  10. Chung‐Pin Li · 1 shared paper, 2020 · strength 0.11
  11. David Cunningham · 1 shared paper, 2020 · strength 0.11
  12. Andrea Wang‐Gillam · 1 shared paper, 2020 · strength 0.11
  13. Teresa Mercade Macarulla · 1 shared paper, 2020 · strength 0.11
  14. Peter Brauchli · 1 shared paper, 2019 · strength 0.09
  15. Piera Gargiulo · 1 shared paper, 2019 · strength 0.09
  16. Ákos Szűcs · 1 shared paper, 2017 · strength 0.08
  17. Péter Jenő Hegyi · 1 shared paper, 2017 · strength 0.08
  18. Gábor Lakatos · 1 shared paper, 2017 · strength 0.08
  19. Peter James O'Dwyer · 1 shared paper, 2017 · strength 0.06
  20. G. Deplanque · 1 shared paper, 2017 · strength 0.06
  21. Thomas R. Jeffry Evans · 1 shared paper, 2017 · strength 0.06
  22. Denis Pezet · 1 shared paper, 2017 · strength 0.06
  23. Bohuslav Melichar · 1 shared paper, 2017 · strength 0.06
  24. Alexander S. Rosemurgy · 1 shared paper, 2017 · strength 0.06
  25. Eric Van Cutsem · 1 shared paper, 2017 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.